Dragon09/odtu_chatbot huggingface dataset:
mucociliary adaptations and gut microbiome establishment in xenopus

cell type compositions determine tissue morphologies and functions are adapted during evolution and their changes cause diseases however we do not understand how cell type compositions can be controlled and modified to predictively achieve different organ functions the goal of the magix project is to understand the developmental mechanisms controlling cell type compositions and to mechanistically link variations of cell type compositions to physiological properties of tissues in development and disease we will use mucociliary epithelia as they provide an optimal system to study how adaptations of cell type compositions are regulated and how they determine organ functions they build on a conserved generegulatory network to generate epithelia with different functions across species and organs derived from all three germ layers we hypothesize that key epigenetic patterning and remodeling mechanisms are used in a modified fashion to generate different functions and morphologies in different organs in this project we will establish two new vertebrate mucociliary model systems in the xenopus foregut and the mouse esophagus multimodal resources and integratively analyze data across models we will then test a series of hypotheses experimentally to gain insights into the mechanisms regulating mucociliary cell type compositions their adaptations and to model mucociliary patterning in silico lastly the developmental functions of foregut mucociliary epithelia in xenopus and mice will be investigated to reveal potential contributions to gut microbiome establishment thereby uncovering a new role for mucociliary epithelia in vertebrate development using a range of stateoftheart techniques the magix project will study mucociliary adaptations to resolve fundamental questions in cell and developmental biology and to provide translational insights into human diseases that kill 8 mio people per year chronic airway diseases cancers motile ciliopathies
integrating gan nanowire heterostructures on 2d heterogeneous platforms for photodetection

iiinitride semiconductors ganalgan are strategic materials for photodetection in a broad spectral range from deep ultraviolet to far infrared these domains can be addressed thanks to interband and intersubband transitions respectively which cover wavelengths inaccessible to standard iiiv semiconductors heterogeneous integration of iiin nanowires nws on 2d materials at the same time opens new technological opportunities for advanced optoelectronics and presents fundamental interest to elucidate the physics of van der waals epitaxy vdwe available research on epitaxial growth of gan nws on 2d graphene has demonstrated its promise however the scope for improvement remains limited a number of questions with fundamental significance eg the influence of the 2d material in nw growth controlling factors for nw sizesizedistribution and generalized understanding of vdwe with experimental authentication remain open integrasion proposes to address these open questions and to achieve a general understanding of vdwe of nitrides on 2d materials for advanced optoelectronic devices to reach this goal ganalgan nws will be grown on 2d transition metal dichalcogenides ws2 and comparative analysis will be performed with growth on graphene the fundamentals of growth process will be assessed experimentally and theoretically emphasizing the impact of 2d materials on the nw growth which is pivotal for heterojunction formation ganalgan heterojunctions in multiquantum well structure will be grown on 2d platforms to demonstrate interband uv photodetection as well as intersubband photodetection in mid and farinfrared domains besides heterogeneous integration of gan nws on 2d platforms will facilitate the postgrowth transfer of iiin nws to flexible substrates where monolithic integration is not possible integrasion will address these three key aspects i heterogenous growth ii interbandintersubband photodetection and iii hybrid integration
precision nutrition to optimize immune response for metabolic health

nutrimmune examines how dietary factors affect immune responses across varying degrees of obesityrelated noncommunicable disease ncd severity this focus is crucial given obesitys link to ncds and infection risks the project gathers 6 academic groups and 1 sme across 4 european countries over 4 years and a 43m grant to evaluate the interplay between nutrition glycome microbiome and immune health in obesity and immune impairmentnutrimmune leverages partners i access to european databases and biobanks enabling indepth analysis at cellular and molecular levels ii proficiency in conducting dietary intervention studies in human subjects and iii experience in mechanistic and functional dietglycomemicrobiome interactionsin wp1 the project deciphers phenotypic multiomics and dietary factors responsible for variability in immune checkpoint icp expression and immune impairment in existing cohorts wp2 focuses on a 24week precision nutritional intervention to assess the potential of a proimmune diet to restore t cell fitness in obese subjects wp3 conducts comprehensive profiling before and after the dietary intervention examining innate and adaptive responses cytokine patterns alongside icp labeling wp4 provides mechanistic aspects on how the diet glycome microbiome influence immune health wp5 employs machine learning models to identify predictive markers and signatures for icp expression and altered immunity to identify dietary patterns and food affecting immune function wp6 ensures efficient project management and effective coordination ethics compliance dissemination and exploitation wp7 explores synergies with portfolio projects for challenge goalsthe projects goal is to move from our novel idea that precision nutrition influences immunity via microbiome and glycome and present validated proofofconcept evidence for nutritional recommendations and future food development
development of an aibased algorithm for contrast agent dose reduction in magnetic resonance imaging

in cranial magnetic resonance tomography cmrt the administration of contrast agent facilitates diagnosis of various pathologies such as metastases due to contrast agent enhancement patients undergoing a medically indicated cmrt receive 100 of the authorized contrast agent dose ie 01 mmol of gadolinium per kg body weight the main component of mrt contrast agent is gadolinium which is a highly toxic rareearth element which has potential health side effects inter alia allergic reactions and accumulation in the body as well as environmental side effects accumulation in the tap waterdue to the aforementioned issues the reduction of contrast agent dose in cmrt is highly desirable to tackle this issue katerina deikehofmann from the clinic for neuroradiology at the university hospital bonn together with colleagues and collaborators from the institute of mathematics and life sciences developed an artificial intelligence aibased algorithm that allows for contrast agent reduction called smartcontrast until today more than 1000 prospective data sets were acquired at seven different clinics and smartcontrast showed excellent generalizibility thus katerina deikehofmann founded the reliosvision gmbh as a spinoff of the university bonn to commercialize smartcontrast her goal is to advance the clinical standard by combining knowledge from the areas of medicine mathematical image processing computer vision and artificial intelligence
breast milk biomimetic nano particles as a versatile noninvasive oral drug delivery tool

we propose to use human breast milk cells to engineer breast milk biomimetic nanoparticles np milkosomes to shuttle medicines orally into the body that under other conditions would not be able to distribute properly milkosomes are cellular membrane proteinfunctionalized phospholipid np ie liposomes and they are hypothesized to cross the gastrointestinal gi tract while protecting their therapeutic cargo and serve as a novel way to improve oral therapy outcomes unfortunately although oral delivery of therapeutic agents is the most patientpreferred route of administration because it is painless and convenient it entails enormous challenges specifically large molecules such as messenger rna and proteins cannot be delivered orally due to their chemical and enzymatic degradation in the gi tract and poor intestines permeability to these molecules interestingly cells which are a thousand times bigger than these large molecules remain intact therefore they can get out of the gi tract due to membrane proteinmediated biological processes and make their way into our bodies herein we aim to 1 identify and assess the breast milk cell populations which cross the gi tract into the infant body after breastfeeding in vivo 2 fabricate and characterize milkosomes 3 evaluate milkosomes ability to cross the gi tract biological barrier using in vitro and exhuman models and 4 test milkosomes therapeutic efficacy in vivo using two diverse in vivo models thus we will harness the specific and unique biological function of these gi tractcrossing native cells while protecting their therapeutic cargo from degradation using the phospholipid np backbone our findings will increase our fundamental understanding of cellular and np trafficking through the gi tract and lay the foundations for designing a next generation and noninvasive nanobiomimetic oral drug delivery technology that may affect public health worldwide
pediatric hospitals as european drivers for multiparty computation and synthetic data generation capabilities across clinical specialties and data types

crossborder collaboration can tackle the challenges in accessing relevant health data essential for international collaboration between scientists and clinicians researchers and health industry privacy concerns and regulations on personal data have made the sharing of health data increasingly complex and timeconsuming for data controllers thus severely limiting the access of smes researchers and innovators to health data further complications in crossborder collaboration arise from differences in interpreting the eu gdpr national regulations and heterogenous and changing data permit processes at hospital sites the phems project will provide european childrens hospitals with a decentralized and open health data ecosystem concept consisting of technical components and governance frameworks the objective is to facilitate access to health data advance federated health data analysis and build services for the ondemand generation of shareable synthetized and anonymized datasets to achieve this the project will focus on bridging the gaps in data access and use especially in the integration of ethical legal and technical requirements including the responsibilities of data controllers and the rights of data subjects this will allow health data controllers to engage in collaboration without losing control on compliance with respect to gdpr national legislation or internal policies of their organizationthe techniques and tools for generating algorithmically anonymized and synthetic datasets will undergo robust validation processes through three clinical use cases conducted by the european childrens hospitals organisation echo community the goal is to assess the usage of customgenerated synthetic data with reallife questions data users such as researchers smes innovators and the pharmaceutical and medtech industry will be engaged through community building hackathons and interaction with relevant european largescale initiatives
a training network on the design of precision therapeutics that target key glycan motifs implicated in cancer

glycoscience has gained such significant technological advances over the past decade that it is now poised for giving an unprecedented contribution to highdemanding societal needs glycandrug is a glycoscienceoriented dn that aims for the first time to take a step ahead in the design of precision therapeutics targeting key glycan motifs implicated in cancer these glycans are fingerprints of many cancers thus their targeting has the striking potential to overcome cancer heterogeneity that limits the current targeted therapies providing new opportunities for the discovery of precision therapeuticsthe credibility and high quality of glycandrug are ensured by toplevel glycoscientists from 9 academic institutions 8eu 1us and 6 smes which encompass complementary and intersectoral expertise and unique stateoftheart technological tools to train 10 doctoral candidates dcs glycandrug focuses on the precise inhibition of the expression of cancerassociated glycans and the development of cuttingedge tools for their targeting the unique combination of scientific excellence in interdisciplinary fields and industry knowhow will cover the entire process from obtaining fundamental insights to the implementation of innovative solutions glycandrug aims at creating a critical mass of uniquely skilled graduates in glycanbased therapies to this aim we will equip dcs with a thorough multifaceted knowledge of the potential of glycoscience in the discovery of cancer precision therapeutics and the necessary transferable skills this will put dcs in an advantageous position for job opportunities in both academia and industrydeciphering the glycome expands the frontiers of knowledge and discovery and enables addressing fundamental challenges in cancer therefore glycandrug dn will strengthen the european innovation capacity by bringing new glycoscience concepts in the development of cancer precision therapeutics to market and policy stakeholders
pushing forward the market potential and business models of waste heat valorisation by fullscale demonstration of nextgen heat upgrade technologies in various industrial contexts

as part of the eu strategic agenda to build a climateneutral and green europe increasing energy efficiency of industry is among the priorities of the green deal process heat has a significant weight in the total energy demand of the european industry and increased energy efficiency of industry through the recovery and upgrade of waste heat is one of the first steps towards decarbonization in the industrial sector although different heat upgrade technologies exist their wide deployment is not taking place due to different technical and nontechnical barriers hindering the uptake push2heat will aim to overcome these implementation barriers and push forward the market potential and business models of heat upgrade technologies by real full scale demonstration of different heat upgrade systems in relevant industrial sectors with high waste heat recovery and upgrading potential with supply temperature in the range 90160cdifferent heat upgrade technologies will be scaledup to optimize their efficiency and economic performance and demonstrated in selected industrial demosites covering a representative sample of the most relevant industrial processes with heat recovery potentialeconomic and country specific regulatory barriers summed up to the technical ones greatly influence the deployment of the heat upgrade technologies to tackle this push2heat intends to demonstrate suitable busines models and dedicated exploitation roadmaps for a higher penetration of heat upgrade systems aiming to contribute to meet the industry decarbonization targets for achieving its ambitions push2heat consortium gathers different heat upgrade technology manufacturers industrial endusers where demonstrations will take place engineering and business oriented companies as well as expert rtd partners in the field together with the european association representing the heat upgrade technologies stakeholders
early colorectal cancer patienttargeted and organ preserving treatment ecopop

incidence and mortality of colorectal cancer crc is the second leading cause of cancer death in europe with current screening programs in most european countries many crcs are detected in an early and curable stage with excellent prognosis the current standard treatment for early crc is surgical tumour removal this is considered as overly invasive especially for the growing number of elderly and frail patients expanding technical possibilities of local tumour removal by flexible endoscopy along with initial data supporting its oncological safety open the way to organ preserving therapy this may result in avoiding surgery and improved patients quality of life qol however highquality longterm oncological outcome data of endoscopic removal as compared to surgery are lacking and precise oncological risk criteria prior to the start of the therapy are urgently needed the current project has two major aims a to assess oncological efficacy safety and patient qol of local endoscopic removal of early crc as compared to surgery in 3 randomized trials and b to develop and test criteria in this patient population to primarily identify highrisk lesions based on novel biomarkers endoscopic imaging and other clinical criteria also within an artificial intelligenceguided treatment algorithm we propose to provide stateoftheart assessment of new sustainable less invasive treatment modalities for earlystage crc and determine patient preferences around these therapies we will perform large international headtohead randomized clinical trials these trials will allow carbon cost effectiveness analyses biomarker research and development of clinical practice guidelines to carve out the nextgeneration best clinical practice for patients with earlystage crc our proposal aims at less invasive sustainable organpreserving therapies maintaining high oncological efficacy and helping physicians and patients to perform individual shared decisionmaking
rebuilding joint surface to prevent pain and immobility

a healthy layer of articular cartilage at the end of bones in joints is essential for painless movement when cartilage is damaged it has minimal innate regenerative properties and there is no effective medical cure cartilage damage seriously reduce quality of life and has severe economic impact since loss of cartilage leads to osteoarthritis oa that causes hundreds of billions of euros healthcare and related costs annuallymany attempts have been made to restore joint surface cartilage but the tissue has shown to be extremely difficult to rebuildaskel has developed a unique way to rebuild joint surfaces for painfree movement copla is a biodegradable implant that creates a weightadaptive microenvironment in the damaged site enabling quick rehabilitation and cartilage regeneration to prevent oacopla will become the gold standard for early cartilage repair with rapid recovery and longterm results ensuring painfree movement high quality of life and prevention of oa
reprogramming the reactivity of maingroup compounds for capturing and activating methane and dinitrogen

the activation of chemical bonds is fundamental to every chemical transformation while reactions mediated by transitionmetal catalysts are known for more than a century the last decade witnessed spectacular developments in the emerging area of catalysis mediated by nonmetallic species among these new chemical entities made from earthabundant and inexpensive maingroup elements lewis acidbase pairs and bifunctional elementligand systems mimicking the behavior of transitionmetals rapidly revolutionized the activation modes of chemical bonds in the project byond i will establish new molecular engineering strategies and develop unprecedented maingroup catalysts embedded in cageshaped and curved molecular scaffolds groundbreaking molecules escaping the established structural theories will become the initial focus of my project including the creation of nonplanar b al c and si centered lewis superacids with unmatched reactivities i will push the frontiers of knowledge of chemical bonding by exploring unusual boronelements bonding situations and advance the design of maingroup catalysts beyond the stateoftheart unprecedented ch bond functionalization processes will be developed and exploited for hydrocarbons transformation through the concept of low reorganization energy catalysts the activation of dinitrogen with unique maingroup superacids and bases will finally be tackled a pioneering step toward the uncharted territory of catalytic n2 activation and conversion without transitionmetal complexes these goals will be accomplished through a multidisciplinary approach built on my expertise in mechanistic investigations spectroscopic and kinetics methods organometallic and main group chemistry the project byond will deliver extraordinary solutions for chemists to reach new chemical reactivities beyond the actual limits and will inspire scientists to develop innovative sustainable and costeffective chemical processes
hlahomozygous ipsccardiomyocyte aggregate manufacturing technologies for allogenic cell therapy to the heart

heal will focus on general bottlenecks to induced pluripotent stem cell therapies with a particular focus on heart failure which remains a major cause of morbidity and mortality with very few treatment optionshlahomozygous cell line derived cardiomyocyte aggregates offer the prospect of a restorative heart therapy applicable to large patient populations and to overcome economic barriers associated with autologous approaches by developing solutions for their massproduction and cryopreservation we will enable allogeneic treatment with minimum requirements for immunosuppressionassays for assessment of immunogenicity will provide data for the development of an artificial intelligence powered algorithm to predict recipientss immune responses for personalised design of immunosuppression protocolsa potency assay to assure product effectiveness will be developed together with assays of tumorigenicity in vitro and in vivo that meet and exceed current regulatory requirements a genetic integrity pipeline defining the most sensitive assays for rigorous assessment will be developed and a rescue tool in the form of a biallelic suicide gene for programmed cell death will add to the safety toolbox for the therapyoptimisation of cellproduct administration in terms of retention and engraftment including catheterbased delivery as minimally invasive alternative to surgical application and assessment of risks of graftinduced arrhythmia will be determined in a pig model early dialogues via established links to the regulatory authorities will ensure proper development according to gmp requirementsfreedom to operate and licensing strategies with a health technology and infrastructure assessment of european centres will set the scene for approval of the cell product and related assays and protocols for storage and distribution required to progress towards a first in man study of cellbased heart repair